 SEOUL, South Korea and LOS ANGELES, June 14, 2021 PRNewswire -- KT Corporation and NeuroSigma, Inc. jointly announced signing of a memorandum of understanding, forming a strategic partnership to develop and commercialize, inside and outside of Korea, electronic therapies treating neurological and neuropsychological disorders, including ADHD, depression, and epilepsy. NeuroSigma is the developer of the Monarch eTNS System , which uses non-invasive external trigeminal nerve stimulation eTNS to treat neurological and neuropsychiatric indications, and is the first device-based, non-drug therapy approved by the FDA to treat pediatric ADHD. 